CCIA
CRSP icon

Campbell & Co Investment Adviser’s CRISPR Therapeutics CRSP Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.86M Buy
+107,529
New +$5.67M 0.31% 48
2024
Q4 		– Sell
-18,322
Closed -$861K – 1103
2024
Q3 		$861K Buy
+18,322
New +$930K 0.06% 497
2024
Q2 		– Sell
-8,918
Closed -$608K – 1087
2024
Q1 		$608K Sell
8,918
-9,856
-52% -$706K 0.05% 616
2023
Q4 		$1.18M Buy
+18,774
New +$1.04M 0.11% 317

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Campbell & Co Investment Adviser's CRSP Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 107,529 shares worth $5.86M. The stake represents 0.31% of the portfolio and ranks #48 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in CRSP as recently as Q3 2024.

Campbell & Co Investment Adviser first reported a position in CRSP in Q4 2023 and has held it in 4 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Campbell & Co Investment Adviser held 107,529 shares of CRISPR Therapeutics worth $5.86M as of Q2 2026.
  • CRISPR Therapeutics was a new Campbell & Co Investment Adviser position in Q2 2026.
  • CRISPR Therapeutics made up 0.31% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #48 holding.
  • Campbell & Co Investment Adviser first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.